RxDoctor Payments Data

Richard Lee, MD

Family Medicine · Palo Alto, CANPI 1285625236

Payments from drug & device makers

$5,654in general payments, 2019–2025

Across 185 payments — averaging $30.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • AbbVie$1K
  • Pfizer$696
  • Exact Sciences$196
  • Eisai Inc.$171
  • Biohaven Pharmaceuticals, Inc.$145
  • plus $1K from 19 others

What the payments were for

  • Consulting fees$1,20021%
  • Travel & lodging$2815%
  • Food & beverage$4,17374%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,654 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$40,214
Medicare patients
114
Services billed
439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban21$14,595
MounjaroTirzepatide12$12,313
JanuviaSitagliptin Phosphate16$11,547
LinzessLinaclotide13$6,722
Testosterone15$5,294
SynthroidLevothyroxine Sodium35$2,777
Liothyronine Sodium45$2,280
Estradiol13$1,576
Levothyroxine Sodium96$1,316
Estradiol (Twice Weekly)Estradiol12$784
Celecoxib22$688
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen21$661
Ondansetron OdtOndansetron14$599
ValacyclovirValacyclovir Hcl18$572
Lorazepam44$525

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$696$14,59521 claims
Lilly USA, LLCMounjaro$136$12,31312 claims
MerckJanuvia$21$11,54716 claims
AbbVieLinzess, Synthroid$1,326$9,49948 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Palo Alto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →